Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?

Zinger Key Points
  • Emergent BioSolutions reports quarterly earnings of 59 cents per share, beating the analyst consensus estimate.
  • Quarterly sales clock in at $300.4 million which beat the analyst consensus estimate of $224.5 million by 33.81%.

Emergent BioSolutions, Inc. EBS shares surged higher Thursday after the company announced operational changes to stabilize its financial position and reported first-quarter financial results.

The Details:

Emergent reported quarterly earnings of 59 cents per share, which beat the analyst consensus estimate of losses of 83 cents by 171.08%. 

Quarterly sales clocked in at $300.4 million, which beat the analyst consensus estimate of $224.5 million by 33.81% and represents an 82.84% increase from the same period last year.

The company also announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities and restructures its enterprise workforce to improve its performance and profitability. 

Emergent will shut down both its Baltimore-Bayview Drug Substance manufacturing facility and Rockville, Maryland Drug Product facility. The company will also reduce its workforce by 300 employees across all areas of the company, and eliminate approximately 85 positions that are currently vacant. 

The company expects savings of approximately $80 million when fully implemented. Costs associated with the restructuring plan are estimated to be approximately $18 million to $21 million and are expected to be primarily incurred in the second half of 2024.

Emergent raised its revenue guidance for 2024 to between $1 billion and $1.1 billion. 

Related News: Enovix Stock Soars On Blockbuster Q1 Sales

EBS Stock Prediction 2024:

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Emergent BioSolutions, an investor could make an assessment about a stock's long term prospects using a moving average and trend line.

If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Emergent BioSolutions, the 200-day moving average sits at $3.04, according to Benzinga Pro, which is below the current price of $3.99. For more on charts and trend lines, see a description here.

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

EBS Price Action: According to Benzinga Pro, Emergent BioSolutions shares closed 70.9% higher at $3.30 on Thursday. 

Image: Gerd Altmann from Pixabay

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsTop StoriesMoversStories That Matterwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!